Vasoactive intestinal peptide enhancement of antigen-induced differentiation of a cultured line of mouse thymocytes

被引:31
作者
Pankhaniya, R
Jabrane-Ferrat, N
Gaufo, GO
Sreedharan, SP
Dazin, P
Kaye, J
Goetzl, EJ
机构
[1] Univ Calif San Francisco, Dept Med & Microbiol, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA
[3] Scripps Res Inst, La Jolla, CA 92037 USA
关键词
neuropeptide; immunology; T lymphocyte; receptor; apoptosis;
D O I
10.1096/fasebj.12.1.119
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The prominence of vasoactive intestinal peptide (VIP) in rodent thymic neurons suggested that this potent mediator of T cell functions may alter developmental responses of thymocytes to T cell receptor (TCR) -dependent stimulation, CD4(+)8(+) DPK cells derived from a thymic lymphoma of a TCR transgenic mouse respond to pigeon cytochrome C (PCC) antigen in association with distinct I-E MHC II haplotypes on antigen-presenting cells (APCs) by differentiating into CD4(+)8(-) T cells, The specific recognition of VIP by two types of homologous C-protein-coupled receptors (VIPR1 and VIPR2) on DPK cells was attributable predominantly to VIPR1 before and to VIPR2 after exposure to APCs and PCC, as assessed by quantification of the respective mRNAs, PCC-evoked differentiation of DPK cells was enhanced significantly by 1 to 100 nM VIP after 3 to 4 days, The effects of VIP analogs with VIPR type selectivity implied that VIP enhancement of differentiation of DPK cells was mediated principally by VIPR2, Differential reduction in the expression of each type of VIPR by transfection of DPK cells with plasmids encoding the respective antisense mRNAs confirmed the central role of VIPR2 in VIP-enhanced conversion to CD4(+)8(-) T cells. The suppression of DPK cell differentiation by inhibitors of adenylyl cyclase and protein kinase A suggested a transductional role for VIP-elicited increases in [cAMP](i). That the changes in frequency of CD4(+)8(+) and CD4(+)8(-) DPK cells reflected principally differentiation was supported by the lack of consistent differences between the two subsets in the effects of VIP and VIPR2 agonist on cell number, viability, apoptosis, and proliferation, VIP may be one endogenous mediator that explains the unique thymic microenvironment for topographically specific development of T cells.
引用
收藏
页码:119 / 127
页数:9
相关论文
共 36 条
[1]   NEUROPEPTIDES IN THE RESPIRATORY-TRACT .1. [J].
BARNES, PJ ;
BARANIUK, JN ;
BELVISI, MG .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 144 (05) :1187-1198
[2]   The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation [J].
Bellinger, DL ;
Lorton, D ;
Brouxhon, S ;
Felten, S ;
Felten, DL .
ADVANCES IN NEUROIMMUNOLOGY, 1996, 6 (01) :5-27
[3]   VASOACTIVE INTESTINAL POLYPEPTIDE MODULATES THE IN-VITRO IMMUNOGLOBULIN-A PRODUCTION BY INTESTINAL LAMINA PROPRIA LYMPHOCYTES [J].
BOIRIVANT, M ;
FAIS, S ;
ANNIBALE, B ;
AGOSTINI, D ;
FAVE, GD ;
PALLONE, F .
GASTROENTEROLOGY, 1994, 106 (03) :576-582
[4]   MULTIPLE NEUROPEPTIDES IN NERVES SUPPLYING MAMMALIAN LYMPH-NODES - MESSENGER CANDIDATES FOR SENSORY AND AUTONOMIC NEUROIMMUNOMODULATION [J].
FINK, T ;
WEIHE, E .
NEUROSCIENCE LETTERS, 1988, 90 (1-2) :39-44
[5]   Vasoactive intestinal peptide induces S alpha/S mu switch circular DNA in human B cells [J].
Fujieda, S ;
Waschek, JA ;
Zhang, K ;
Saxon, A .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (07) :1527-1532
[6]   VASOACTIVE-INTESTINAL-PEPTIDE DOWN-REGULATES THE EXPRESSION OF IL-2 BUT NOT OF IFN-GAMMA FROM STIMULATED MURINE T-LYMPHOCYTES [J].
GANEA, D ;
SUN, L .
JOURNAL OF NEUROIMMUNOLOGY, 1993, 47 (02) :147-158
[7]  
GOETZL EJ, 1995, J IMMUNOL, V154, P1041
[8]   MEDIATORS OF COMMUNICATION AND ADAPTATION IN THE NEUROENDOCRINE AND IMMUNE-SYSTEMS [J].
GOETZL, EJ ;
SREEDHARAN, SP .
FASEB JOURNAL, 1992, 6 (09) :2646-2652
[9]   Tuning of activation thresholds explains flexibility in the selection and development of T cells in the thymus [J].
Grossman, Z ;
Singer, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (25) :14747-14752
[10]  
Groves T, 1997, J IMMUNOL, V158, P65